Baloira Adolfo
Servicio de Neumología. Complejo Hospitalario de Pontevedra, Pontevedra, Spain.
Arch Bronconeumol. 2010;46 Suppl 8:25-30. doi: 10.1016/S0300-2896(10)70064-8.
Chronic obstructive pulmonary disease (COPD) is one of the most important respiratory diseases, characterized by its multicomponent complexity, with chronic inflammation, increased airway resistance and exacerbations. Several drugs are currently available for its treatment, which act on distinct targets. Bronchodilators, especially prolonged-action bronchodilators, are the most potent and there are two groups: beta-2 mimetics and anticholinergics. Inhaled corticosteroids are the main anti-inflammatory drugs but have modest efficacy and their use is reserved for patients with severe disease and frequent exacerbations and/or asthma traits. Associating these three drugs can improve symptom control, improve quality of life and reduce the number of exacerbations. The present article reviews the evidence supporting this triple combination, as well as published studies.
慢性阻塞性肺疾病（COPD）是最重要的呼吸系统疾病之一，其特征在于多组分复杂性，伴有慢性炎症、气道阻力增加和病情加重。目前有几种药物可用于治疗，它们作用于不同的靶点。支气管扩张剂，尤其是长效支气管扩张剂，是最有效的，有两类：β-2 激动剂和抗胆碱能药物。吸入性糖皮质激素是主要的抗炎药物，但疗效一般，仅用于重症、频繁病情加重和/或有哮喘特征的患者。联合使用这三种药物可改善症状控制、提高生活质量并减少病情加重次数。本文综述了支持这种三联疗法的证据以及已发表的研究。
